May thrombopoietin be a useful marker of sepsis severity assessment in patients with SIRS entering the emergency department?

Clinical Chemistry and Laboratory Medicine

Volumn 52, Issue 10, 2014, Pages 1479-1483

  Segre, Elisabetta ^a,b   Pigozzi, Luca ^a,b   Lison, Davide ^a,b   Pivetta, Emanuele ^a,b   Bosco, Ornella ^c   Vizio, Barbara ^c   Suppo, Umberto ^a,b   Turvani, Fabrizio ^a,b   Morello, Fulvio ^c   Battista, Stefania ^c   Moiraghi, Corrado ^c   Montrucchio, Giuseppe ^c   Lupia, Enrico ^a,b  

^a UNIVERSITY OF TURIN   (Italy)

^b CITTÀ DELLA SALUTE E DELLA SCIENZA HOSPITAL   (Italy)

^c Emergency Medicine Unit   (Italy)

Author keywords

Biomarker; Sepsis; Systemic inflammatory response syndrome (SIRS); Thrombopoietin

Indexed keywords

THROMBOPOIETIN; BIOLOGICAL MARKER;

ACUTE HEART FAILURE; ACUTE PANCREATITIS; AGED; ALLERGIC REACTION; ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; EARLY DIAGNOSIS; EMERGENCY WARD; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OBSERVATIONAL STUDY; PATIENT ASSESSMENT; PRIORITY JOURNAL; PROSPECTIVE STUDY; SEPSIS; SEPTIC SHOCK; BLOOD; CLINICAL TRIAL; EMERGENCY HEALTH SERVICE;

AGED; BIOLOGICAL MARKERS; EMERGENCY SERVICE, HOSPITAL; FEMALE; HUMANS; MALE; SEPSIS; THROMBOPOIETIN;

EID: 84921367511     PISSN: 14346621     EISSN: 14374331     Source Type: Journal    
DOI: 10.1515/cclm-2014-0219     Document Type: Article

References (33)

1. Kaushansky K. Thrombopoietin: a tool for understanding thrombopoiesis. J Thromb Haemost 2003;1:1587-92.
2. Chou FS, Mulloy JC. The thrombopoietin/Mpl pathway in hematopoiesis and leukemogenesis. J Cell Biochem 2011;112:1491-8.
3. Bartley TD, Bogenberger J, Hunt P, Li YS, Lu HS, Martin F, et al. Identification and cloning of a megakaryocyte growth and development factor that is a ligand for the cytokine receptor Mpl. Cell 1994;77:1117-24.
4. de Sauvage FJ, Hass PE, Spencer SD, Malloy BE, Gurney AL, Spencer SA, et al. Stimulation of megakaryocytopoiesis and thrombopoiesis by the c-Mpl ligand. Nature 1994;369: 533-8.
5. Ezumi Y, Takayama H, Okuma M. Thrombopoietin, c-Mpl ligand, induces tyrosine phosphorylation of TYK2, JAK2, and STAT3, and enhances agonists-induced aggregation in platelets in vitro. FEBS Lett 1995;374:48-52.
6. Montrucchio G, Brizzi MF, Calosso G, Marengo S, Pegoraro L, Camussi G. Effects of recombinant human megakaryocyte growth and development factor on platelet activation. Blood 1996;87:2762-8.
7. Oda A, Miyakawa Y, Druker BJ, Ozaki K, Yabusaki K, Shirasawa Y, et al. Thrombopoietin primes human platelet aggregation induced by shear stress and by multiple agonists. Blood 1996;87:4664-70.
8. Tibbles HE, Navara CS, Hupke MA, Vassilev AO, Uckun FM. Thrombopoietin induces p-selectin expression on platelets and subsequent platelet/leukocyte interactions. Biochem Biophys Res Commun 2002;292:987-91.
9. Lupia E, Bosco O, Bergerone S, Dondi AE, Goffi A, Oliaro E, et al. Thrombopoietin contributes to enhanced platelet activation in patients with unstable angina. J Am Coll Cardiol 2006;48: 2195-203.
10. Lupia E, Bosco O, Goffi A, Poletto C, Locatelli S, Spatola T, et al. Thrombopoietin contributes to enhanced platelet activation in cigarette smokers. Atherosclerosis 2010;210:314-9.
11. Lupia E, Goffi A, Bosco O, Montrucchio G. Thrombopoietin as biomarker and mediator of cardiovascular damage in critical diseases. Mediators Inflamm 2012;2012:390892.
12. Zakynthinos SG, Papanikolaou S, Theodoridis T, Zakynthinos EG, Christopoulou-Kokkinou V, et al. Sepsis severity is the major determinant of circulating thrombopoietin levels in septic patients. Crit Care Med 2004;32:1004-10.
13. Dellinger RP, Levy MM, Rhodes A, Annane D, Gerlach H, Opal SM, et al. Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2012. Crit Care Med 2012;41:580-637.
14. Angus DC, van der Poll T. Severe sepsis and septic shock. N Engl J Med 2013;369:840-51.
15. Rivers E, Nguyen B, Havstad S, Ressler J, Muzzin A, Knoblich B, et al. Early goal-directed therapy in the treatment of severe sepsis and septic shock. N Engl J Med 2001; 345:1368-77.
16. Dellinger RP, Levy MM, Rhodes A, Annane D, Gerlach H, Opal SM, et al. Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock, 2012. Intensive Care Med 2012;39:165-228.
17. Levy MM, Macias WL, Vincent JL, Russell JA, Silva E, Trzaskoma B, et al. Early changes in organ function predict eventual survival in severe sepsis. Crit Care Med 2005;33:2194-201.
18. Kumar A, Roberts D, Wood KE, Light B, Parrillo JE, Sharma S, et al. Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Crit Care Med 2006;34:1589-96.
19. Martin GS, Mannino DM, Eaton S, Moss M. The epidemiology of sepsis in the United States from 1979 through 2000. N Engl J Med 2003;348:1546-54.
20. Annane D, Aegerter P, Jars-Guincestre MC, Guidet B. Current epidemiology of septic shock: the CUB-Rea network. Am J Respir Crit Care Med 2003;168:165-72.
21. Ventetuolo CE, Levy MM. Biomarkers: diagnosis and risk assessment in sepsis. Clin Chest Med 2008;29:591-603, vii.
22. Vincent JL, Beumier M. Diagnostic and prognostic markers in sepsis. Expert Rev Anti Infect Ther 2013;11:265-75.
23. Faix JD. Biomarkers of sepsis. Crit Rev Clin Lab Sci 2013; 50:23-36.
24. Chan T, Gu F. Early diagnosis of sepsis using serum biomarkers. Expert Rev Mol Diagn 2011;11:487-96.
25. Stohlawetz P, Folman CC, von dem Borne AE, Pernerstorfer T, Eichler HG, Panzer S, et al. Effects of endotoxemia on thrombopoiesis in men. Thromb Haemost 1999;81:613-7.
26. Ishiguro A, Suzuki Y, Mito M, Shimbo T, Matsubara K, Kato T, et al. Elevation of serum thrombopoietin precedes thrombocytosis in acute infections. Br J Haematol 2002;116:612-8.
27. Colarizi P, Fiorucci P, Caradonna A, Ficuccilli F, Mancuso M, Papoff P. Circulating thrombopoietin levels in neonates with infection. Acta Paediatr 1999;88:332-7.
28. Bjerre A, Ovstebo R, Kierulf P, Halvorsen S, Brandtzaeg P. Fulminant meningococcal septicemia: dissociation between plasma thrombopoietin levels and platelet counts. Clin Infect Dis 2000;30:643-7.
29. Reinhold A, Zhang J, Gessner R, Felderhoff-Mueser U, Obladen M, Dame C. High thrombopoietin concentrations in the cerebrospinal fluid of neonates with sepsis and intraventricular hemorrhage may contribute to brain damage. J Interferon Cytokine Res 2007;27:137-45.
30. Oygur N, Tunga M, Mumcu Y, Yesilipek A, Gura A, Coskun M, et al. Thrombopoietin levels of thrombocytopenic term and preterm newborns with infection. Am J Perinatol 2001;18: 279-86.
31. Folman CC, Linthorst GE, van Mourik J, van Willigen G, de Jonge E, Levi M, et al. Platelets release thrombopoietin (TPO) upon activation: another regulatory loop in thrombocytopoiesis? Thromb Haemost 2000;83:923-30.
32. Lupia E, Bosco O, Mariano F, Dondi AE, Goffi A, Spatola T, et al. Elevated thrombopoietin in plasma of burned patients without and with sepsis enhances platelet activation. J Thromb Haemost 2009;7:1000-8.
33. Lupia E, Spatola T, Cuccurullo A, Bosco O, Mariano F, Pucci A, et al. Thrombopoietin modulates cardiac contractility in vitro and contributes to myocardial depressing activity of septic shock serum. Basic Res Cardiol 2010;105:609-20.